Research programme: haemophilia A cell therapy - Sernova

Drug Profile

Research programme: haemophilia A cell therapy - Sernova

Latest Information Update: 21 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sernova Corp
  • Class Cell therapies
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Haemophilia A; Type 1 diabetes mellitus

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 01 Nov 2015 Sernova enters into collaboration with University Hospital of Wurzburg, Integrierte Management Systeme, Universita del Piemonte Orientale Amedeo Avogadro, Loughborough University and GABO:mi to develop a haemophilia A cell therapy
  • 23 Apr 2015 Sernova receives patent allowance for Cell Pouch™ technology in USA
  • 14 May 2014 Sernova receives patent allowance for Cell Pouch™ and therapeutic cell transplantation technologies in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top